Known targets — ChEMBL curated mechanism
BTKCACNA1CCACNA1DCACNA1FCACNA1SCACNA2D1CACNA2D2DRD2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQHRH1HTR2AP2RY12
The experimentally established mechanism targets of Morpholine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | HTR6 | P50406 | 5/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | HTR2C | P28335 | 1/20 | 0.39 |
| ▸ | HTR2B | P41595 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL1589534 | 0.86 | TSHR (0.73) | TSHRSMN1; SMN2HTR6POLBCYP2D6 | |
| Dioxane SCHEMBL9860485 | 0.86 | TSHR (0.73) | TSHRSMN1; SMN2HTR6PKMPOLB | |
| Pyrrolidine SCHEMBL2940824 | 0.82 | TSHR (0.67) | TSHRSMN1; SMN2HTR6POLBCYP2D6 | |
| Tetrahydrofuran SCHEMBL27621833 | 0.82 | SMN1; SMN2 (0.67) | TSHRSMN1; SMN2HTR6PKMPOLB | |
| Morpholine SCHEMBL890524 | 0.82 | L3MBTL1 (0.43) | SMN1; SMN2PKMCYP2D6GAAKDM4E | |
| Azetidine SCHEMBL28177662 | 0.82 | TSHR (0.73) | TSHRSMN1; SMN2HTR6POLBCYP2D6 | |
| Morpholine SCHEMBL28900820 | 0.81 | ALDH1A1 (0.59) | TSHRSMN1; SMN2HTR6PKMPOLB | |
| SCHEMBL6408322 | 0.81 | SMN1; SMN2 (0.64) | TSHRSMN1; SMN2PKMPOLBCYP2D6 | |
| Piperidine SCHEMBL3747941 | 0.81 | SMN1; SMN2 (0.64) | TSHRSMN1; SMN2HTR6POLBCYP2D6 | |
| Fluoride SCHEMBL8718922 | 0.79 | TSHR (0.94) | TSHRSMN1; SMN2HTR6POLBCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102149386-A | Novel pharmaceutical composition for treating nociceptive pain | ASTELLAS PHARMA INC | 2011-08-10 | — | — | CN | claimed |
| CN-102149699-A | Novel salt of morpholine derivative | ASTELLAS PHARMA INC | 2011-08-10 | — | — | CN | claimed |
| CN-1950089-A | Morpholine compounds | PFIZER LTD (US) | 2007-04-18 | — | — | CN | claimed |
| EP-0252875-B1 | MICROBICIDAL AGENT | CIBA-GEIGY AG (CH) | 1993-01-27 | — | — | EP | claimed |
| CN-106573453-B | polyester film comprising amorphous polyester | 杜邦帝人薄膜美国有限公司 | 2018-11-13 | — | — | CN | disclosed |
| CN-105531298-B | Electroconductive polymer manufacture monomer liquid and the manufacture method using its electrolytic capacitor | 帝化株式会社 | 2017-11-28 | — | — | CN | disclosed |
| CN-106573453-A | Polyester film comprising amorphous polyester | 杜邦帝人薄膜美国有限公司 | 2017-04-19 | — | — | CN | disclosed |
| CN-104379666-B | Composition for forming cured film, alignment material, and phase difference material | 日产化学工业株式会社 | 2016-10-19 | — | — | CN | disclosed |
| US-20160225531-A1 | A MONOMER LIQUID FOR OF CONDUCTIVE POLYMER PRODUCTION AND A MANUFACTURING METHOD OF AN ELECTROLYTE CAPACITOR USING THE SAME | TAYCA CORPORATION (JP) | 2016-08-04 | — | — | US | disclosed |
| CN-105531298-A | Monomer liquid for production of conductive polymer and method for manufacturing electrolytic capacitor using same | TAYCA CORP | 2016-04-27 | — | — | CN | disclosed |
| CN-102321641-A | From the tobacco cloning of cytochrome P 450 genes | US SMOKELESS TOBACCO CO | 2012-01-18 | — | — | CN | disclosed |
| CN-1867674-B | Cloning of Cytochrome P450 Genes from Tobacco | US SMOKELESS TOBACCO CO | 2011-11-09 | — | — | CN | disclosed |
| CN-102149699-A | Novel salt of morpholine derivative | ASTELLAS PHARMA INC | 2011-08-10 | — | — | CN | disclosed |
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | FISH PAUL VINCENT | 2010-06-03 | — | — | US | disclosed |
| CN-1950089-A | Morpholine compounds | PFIZER LTD (US) | 2007-04-18 | — | — | CN | disclosed |
| CN-1867674-A | Cloning of Cytochrome P450 Genes from Tobacco | US SMOKELESS TOBACCO CO (US) | 2006-11-22 | — | — | CN | disclosed |
| US-5026719-A | Synergistic combination of triazole fungicide and morpholine alkylarylsulfonate | CIBA-GEIGY CORPORATION (US) | 1991-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100137316-A1 | Morpholine Compounds, Pharmaceutically Acceptable Salts Thereof, Pharmaceutical Compositions, and Methods Of Use Thereof | OPRL1, UGT1A1, HTR3B | TSHR 3645/4885SMN1; SMN2 5/4885HTR6 137/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.